Simple Summary Genome-based cancer medicine is becoming the standard of care: the
patient's tumor DNA is first analyzed to identify driver mutations, and this permits later …

Lung cancer ranks as the 2nd most common cancer globally. It's the most prevalent cancer
in men and the 2nd most common in women. The prominent events in EGFR-mutated non …

Gold nanoparticles (GNPs) are emerging as promising modular platforms for antibody-
based cancer therapeutics. Their unique physiochemical properties enable efficient binding …

Lung cancer is a highly aggressive neoplasm and, despite the development of recent
therapies, tumor progression and recurrence following the initial response remains …

The epidermal growth factor receptor (EGFR) plays a crucial role in regulating cellular
growth and survival, and its dysregulation is implicated in various cancers, making it a prime …

Activating EGFR (epidermal growth factor receptor) mutations can be inhibited by specific
tyrosine kinase inhibitors (TKIs), which have changed the landscape of lung cancer therapy …

Lung cancer is a highly aggressive neoplasm and, despite the development of recent
therapies, tumor progression and recurrence following the initial response remains …

Genetic tests play an increasingly pivotal role in predicting disease risks, prognosis and
treatment response in the clinics. However, their interpretation is hindered by the prevalence …